1	The Contribution of Commonly Diagnosed Genetic Disorders to Small for Gestational
2	Age Birth and Subsequent Morbidity and Mortality in Preterm Infants
3	
4	Miles Bomback, MPH, ¹ Selin Everett, BS, ² Alex Lyford, PhD, ³ Rakesh Sahni, MD, ⁴ Faith Kim,
5	MD, ⁴ Caitlin Baptiste, MD, ² Joshua E. Motelow, MD, PhD, ⁵ Veeral Tolia, MD, ^{6,7,8} Reese Clark,
6	MD, ⁶ Thomas Hays, MD, PhD ⁴
7	
8	¹ Feinberg School of Medicine, Northwestern University, Chicago
9	² Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Columbia
10	University Medical Center, New York City
11	³ Middlebury College, Department of Mathematics, Middlebury, Vermont
12	⁴ Division of Neonatology, Department of Pediatrics, Columbia University Irving Medical Center,
13	New York City
14	⁵ Division of Critical Care and Hospital Medicine, Department of Pediatrics, Columbia University
15	Medical Center, New York City
16	⁶ The Pediatrix Center for Research, Education, Quality and Safety, Sunrise, Florida
17	⁷ Division of Neonatology, Department of Pediatrics, Baylor University Medical Center, Dallas,
18	Texas
19	⁸ Pediatrix Medical Group, Dallas, Texas
20	
21	
22	Corresponding Author: Thomas Hays, <u>th2712@cumc.columbia.edu</u> , 622 West 168 th S, Suite PH
23	17W-303, New York, New York, 10032
24	
25	Word Count:
26	

27 Abstract

28 **Objective:**

- 29 Preterm infants born small, vs. appropriate for gestational age (SGA, AGA) are at greater risk
- 30 for morbidity and mortality. The contribution of genetic disorders to preterm SGA birth,
- 31 morbidity, and mortality is unknown. We sought to determine the association between genetic
- 32 disorders and preterm SGA birth, and the association between genetic disorders and morbidity
- 33 or mortality within preterm SGA infants. We hypothesized that genetic disorders were
- 34 significantly associated with both.

35 Study Design:

- 36 This was a retrospective multicenter cohort study of 409 339 infants, born 23–33 weeks'
- 37 gestation between 2000 and 2020. The odds of preterm SGA (vs AGA) birth, and the odds of
- 38 severe morbidity or mortality within SGA preterm infants were determined for infants with

39 genetic disorders, after adjusting for known risk factors.

40 Results:

- 41 Genetic disorders were present in 3.0 and 1.3% of SGA and AGA preterm infants respectively;
- 42 genetic disorders conferred an aOR (95% CI) of 2.06 (1.92, 2.21) of SGA birth. Genetic
- disorders were present in 4.3 of preterm SGA infants with morbidity or mortality and 2.1% of
- 44 preterm SGA infants that did not experience morbidity or mortality. Genetic disorders conferred

45 an aOR (95% CI) of 2.12 (2.66, 3.08) of morbidity or mortality.

46 **Conclusions**:

- 47 Genetic disorders are strongly associated with preterm SGA birth, morbidity, and mortality.
- 48 Clinicians should consider genetic testing of preterm SGA infants, particularly in the setting of
- 49 other comorbidities or anomalies. Prospective, genomic research is needed to clarify the
- 50 contribution of genetic disorders to disease in this population.
- 51
- 52

53

54 Introduction

55 Preterm infants experience a profound burden of morbidity and mortality, and small for 56 gestational age (SGA) birth is one of the strongest clinical risk factors for poor outcomes. ¹⁻⁹ SGA is defined as birth weight less than the 10th percentile or two standard deviations below 57 58 mean for gestational age and sex based on estimates of population distributions.¹⁰⁻¹³ The 59 mechanism(s) by which SGA birth confers clinical risk are largely unknown. Known factors including impaired metabolic reserve explain only a fraction of these outcomes.¹⁴ Although there 60 61 are known risks for SGA birth, including maternal, placental, infectious, genetic, and 62 environmental factors, the etiology of SGA birth is poorly understood. Known risks include maternal.14-16 63

64

The overall contribution of genetic disorders to preterm SGA birth is unknown. Fetal growth 65 66 restriction (FGR) and continued poor fetal growth often impacts the decision to prematurely deliver a fetus. Multiple studies have found genetic disorders associated with FGR.^{17,18} Higher 67 68 rates of aneuploidy and copy number variants are found in FGR, particularly when presenting before 32 weeks' gestation or accompanied by other fetal anomalies.^{19,20} Metanalysis of exome 69 70 and genome sequencing for FGR demonstrated single gene disorders in 4% of isolated FGR and 30% of FGR accompanied by other anomalies.¹⁷ Genetic disorders have been shown to 71 72 contribute to morbidity and severe mortality in related populations as well. Genetic disorders have been found in 6% of stillbirths, 10% of fetal structural anomalies, and in 20% of cohorts of 73 74 pediatric critical illness or perinatal disease.²¹⁻²⁶

75

Given the burden of illness experienced by preterm SGA infants, emerging evidence that
genetic disorders cause FGR and SGA, and evidence that genetic disorders cause critical
illness in related populations, we sought to determine the contribution of commonly diagnosed

79 genetic disorders to preterm SGA birth, morbidity, and mortality. The Pediatrix Clinical

80 Datawarehouse (CDW) contains detailed health records of these infants, including the presence

81 of genetic disorders diagnosed during standard clinical care.

82

83 Materials/Subjects and Methods:

84 This study was approved by the institutional review board of Columbia University with a waiver 85 for informed consent. This was a retrospective multicenter cohort study using the Pediatrix 86 CDW. The CDW includes records from approximately 400 community and academic NICUs 87 (levels I–IV) in 35 US states and Puerto Rico, which provided care to approximately 20% of 88 preterm infants born in the United States during the study period. Data was entered by clinicians 89 using admission, progress, and discharge notes, as well as results from laboratory, imaging, 90 and other diagnostic studies. These data were then extracted, consolidated, and processed to populate the CDW.²⁷ Data included demographic and maternal characteristics, diagnoses made 91 92 by clinicians (genetic disorders, morbidities), and hospital disposition (mortality, discharge 93 home, or transfer). The results of negative test results, including for genetic disorders, were not 94 available. Records of 409 399 infants born from 23 to 33 weeks' gestation, discharged from 95 2000 to 2020 were extracted. Data from NICU admission to discharge were collected. Birth weight was normalized within the cohort by gestational age and sex. Cases were excluded if 96 97 these data were missing. Infants were classified as SGA for normalized birth weight below the 10th percentile or as appropriate for gestational age (AGA) at the 10th percentile or above and 98 less than the 90th percentile. Infants with birth weight greater than the 90th percentile were 99 100 excluded to prevent the confounding impact of poor outcomes in LGA infants. We determined 101 the overlap of this definition with SGA defined by Fenton criteria and by the Eunice Kennedy 102 Shriver National Institute of Child Health and Human Development (NICHD) consensus FGR definition.10,28 103

105 Association of Genetic Disorders with SGA versus AGA birth among preterm infants 106 We performed multiple variable logistic regression of the association of the following maternal 107 and infant characteristics: ethnicity/race (maternal self-declared), maternal age, diagnosis of 108 genetic disorders, the presence of congenital anomalies (defined as clinician diagnosed 109 anomalies of the heart, gastrointestinal tract, brain, lungs, kidneys and urinary tract, or the 110 presence of hydrops), and year of discharge. Congenital anomalies themselves are strongly 111 associated with genetic disorders. Therefore, we tested for an interaction between congenital 112 anomalies and genetic disorders with the outcome of SGA birth.

113

This analysis was also repeated limiting the cohort to infants born following singleton gestation
to test the effect of multiple gestation. Unadjusted odds of SGA versus AGA birth were
determined for each genetic disorder in which SGA birth was observed. The prevalence rate of
SGA birth across maternal age was also determined.

118

119 Association of genetic disorders with morbidity and mortality within preterm SGA infants 120 Next, we evaluated factors associated with severe morbidity or mortality within preterm SGA 121 infants. To limit ascertainment bias, infants transferred after birth or prior to discharge were excluded from the analysis of clinical outcomes.²⁹ Multivariable logistic regression was 122 123 performed for severe morbidity or mortality as a combined clinical outcome. Severe morbidity 124 was defined as any of the following: acute kidney injury (AKI) defined by the diagnosis of 125 oliguria or anuria (ICD-9 788.5 or ICD-10: R34); severe intracranial hemorrhage (ICH) defined 126 as grade III or IV intraventricular hemorrhage by Papile criteria or cystic periventricular leukomalacia;³⁰ medically or surgically treated necrotizing enterocolitis (NEC); severe 127 128 bronchopulmonary dysplasia (BPD) defined as invasive mechanical ventilation at 36 weeks' 129 postmenstrual age; severe retinopathy of prematurity (ROP) defined as need for any medical or 130 surgical intervention; culture-positive sepsis defined by any positive blood or urine culture; or

131 shock defined as administration of any vasopressor or inotrope. The following were covariates: 132 exposure to antenatal betamethasone, mode of delivery (vaginal delivery was treated as 133 reference), phenotypic sex (female was treated as reference given the associated risk of 134 morbidity in male infants),^{31,32} race (White race was treated as reference given thee proportional 135 size), gestational age, birth weight Z-score, discharge year epoch (2000-2004, 2005-2009, 136 2010-2014, 2015-2020), intubation in the first 72 hours of life, presence of a known genetic 137 disorder, and the presence of congenital anomalies. This analysis was repeated limiting the 138 cohort to infants born following singleton gestation to test the effect of multiple gestations. As 139 before, we also tested for an interaction between genetic disorders and congenital anomalies 140 and the outcome of morbidity or mortality. 141 142 Finally, we sought to evaluate how SGA preterm infants with or without congenital anomalies compared to AGA preterm infants with respect to rates of morbidity and mortality. Using AGA 143 144 preterm infants as reference for both analyses, we determined the crude odds ratios (OR) of 145 individual comorbidities for preterm infants born SGA without congenital anomalies and for 146 preterm infants born SGA with congenital anomalies. Analyses were made using RStudio 147 version 2022.07.0 (R Project for Statistical Computing) (eMethods in the Supplement).³³ 148 149 Results 150 378 887 SGA and AGA infants were identified in this cohort (Table 1). Of these, 176 791 151 (46.7%) were female. The mean (SD) gestational age was 30.1 (2.86) weeks, and the mean 152 (SD) birth weight was 1.44 (0.49) kg. Genetic disorders were diagnosed in 5 386 (1.4%) infants.

153 Congenital anomalies were present in 24 463 (6.4%) of infants. 36 985 (9.8%) infants were

defined as SGA. 36 985 infants met this definition, all of whom were below the 10th percentile for

155 NICHD fetal growth (**Supplemental Figure 1**). 33 451 (92.1%) of these infants were also below

156 the Fenton 10th percentile definition of SGA birth.

157

158	Association of Genetic Disorders with SGA versus AGA birth among preterm infants
159	Genetic disorders were present in 1112 (3.0%) of the 36 985 preterm SGA infants and in 4274
160	(1.3%) of the 341 902 preterm AGA infants in this cohort. Multivariable logistic regression
161	demonstrated higher adjusted OR of SGA versus AGA birth for infants born to mothers
162	identifying as Asian or Black (versus White) and lower for those born to mothers identifying as
163	Hispanic (versus White) (Figure 1). Known genetic disorders and congenital anomalies (except
164	for fetal hydrops and pulmonary anomalies) were also found to be associated with SGA birth in
165	preterm infants. SGA birth was not found to vary across the period of this study (2000–2020).
166	Nearly identical results were found for all covariates when this regression was limited to infants
167	born following singleton gestation (Supplemental Figure 2). Greater maternal age was also
168	associated with SGA birth (Figure 3). The association between genetic disorders and SGA birth
169	was not driven by a single genetic disorder. Rather, SGA birth was associated with multiple
170	known diagnoses including trisomy 13, trisomy 18, trisomy 21, Turner syndrome, unspecified
171	aneuploidy, unspecified copy number variant, sickle cell anemia, cystic fibrosis,
172	hypophosphatasia, and the presence of multiple genetic disorders (Supplemental Table 1). As
173	a secondary analysis, we repeated this regression testing for an interaction between the
174	presence of genetic disorders and the presence of any congenital anomaly. We found that these
175	factors each independently associated with SGA versus AGA birth in preterm infants, but we did
176	not find a significant interaction between these factors and SGA birth.
177	
178	Association of genetic disorders with morbidity and mortality within preterm SGA infants
179	We next focused on morbidity and mortality within the subset of 36 985 SGA preterm infants.
180	After excluding infants transferred in or to other facilities, and those with missing data, 28 983
181	SGA preterm infants remained (Figure 2). Genetic disorders were present in 375 (4.3%) of the

182 8810 preterm SGA infants that experienced severe morbidity or mortality as compared to 415

183 (2.1%) of the 20 173 preterm AGA infants that did not experience these outcomes. Antenatal 184 betamethasone, birth in later years, maternal identification as Asian or Black (versus White), 185 increased gestational age, and increased birth weight all were associated with lower adjusted 186 odds of morbidity or mortality. Male sex, maternal identification as Hispanic (versus White), 187 intubation in the first 72 hours of life, the presence of known genetic disorders, or congenital 188 anomalies were associated with greater adjusted odds of morbidity or mortality. Nearly identical 189 results were found for all covariates when this regression was limited to infants born following 190 singleton gestation pregnancy (**Supplemental Figure 3**). Compared to AGA preterm infants, 191 SGA preterm infants with or without other congenital anomalies experienced higher rates of 192 death and every comorbidity, with the exception of severe ICH, which was observed to occur 193 less frequently in infants with isolated SGA status compared to all AGA infants. (Table 2). As a 194 secondary analysis, we repeated this regression with a test for an interaction between the 195 presence of genetic disorders and the presence of any congenital anomaly. We found that SGA 196 preterm infants with genetic disorders and congenital anomalies had an adjusted odds ratio 197 (95% confidence interval) of 1.52 (1.03, 2.27) for severe morbidity or mortality.

198

199 Discussion

The primary finding of our study was that genetic disorders were strongly and nonspecifically associated with preterm SGA birth, morbidity, and mortality. There are important strengths, limitations, and clinical implications of this finding. Our analysis revealed several secondary findings as well: lower birth weight and higher risk of illness in preterm infants with cystic fibrosis and hypophosphatasia, a synergistic risk of illness in infants with congenital anomalies and genetic disorders, and a lower rate of severe ICH in preterm SGA infants without congenital anomalies. In the following we discuss the primary and secondary findings of our research.

207

208 Using a highly generalizable cohort, we found that commonly diagnosed genetic disorders were 209 twice as prevalent in SGA infants compared to AGA infants, and that genetic disorders were 210 strongly associated with SGA birth weight after adjusting for known risk factors. Genetic 211 disorders were also strongly associated with severe morbidity and mortality in this population. 212 We confirmed previously described associations between common aneuploidies and SGA birth, 213 morbidity, and mortality. Interestingly, we found a broad association between genetic disorders 214 and preterm SGA birth. Of the 20 genetic disorders analyzed (including "unspecified" cases of 215 aneuploidy or copy number variants), significant associations with SGA birth were found in 10, 216 and nonsignificant trends towards this association were found in 8. Cystic fibrosis has recently been implicated as a cause of lower birth weight and earlier gestation of birth,³⁴ which our data 217 218 support. We also found evidence of a novel association between hypophosphatasia and 219 preterm SGA birth, as well as significantly greater odds of morbidity or mortality. If confirmed, 220 these findings might illuminate pathogenic mechanisms of growth restriction. 221

222 Multiple gestations have typically been excluded in large cohort studies limiting the 223 generalizability of findings. We found similar results with or without this exclusion. However, we 224 did not evaluate pairwise outcomes within twin or greater multiple gestations. Clinicians and 225 families, particularly in the setting of growth discordant twins, often must consider risks and 226 benefits in timing of delivery. Targeted focus on SGA multiple gestations could help better inform these decisions, as well as validate twin-specific growth charts.³⁵ Unique factors in twin 227 228 pregnancies including unequal placentation, twin-twin transfusion, and birth weight discordance 229 all may influence clinical outcomes, and should be explored further.^{36,37}

230

231 In addition to genetic disorders, we found that congenital anomalies were strongly associated

with preterm SGA birth, morbidity, and mortality. Congenital anomalies of the kidney, heart,

brain, and other organ systems are themselves strongly linked to genetic disorders. It is unclear

if anomalies themselves caused lower birth weight and illness, or if anomalies were the sentinel
features of underlying genetic disorders. A parsimonious explanation is that underlying genetic
disorders contribute to congenital anomalies, poor fetal growth, and severe morbidity. This is
further supported by the finding that genetic disorders and congenital anomalies interacted to
confer synergistically greater risk of morbidity and mortality in SGA preterm infants.

239

240 Intriguingly, preterm SGA infants without congenital anomalies were found to have lower odds 241 of severe ICH compared to AGA infants. Fetal growth restriction and SGA birth have been 242 described as protective against severe intraventricular hemorrhage in extremely preterm (born < 28 weeks' gestation) infants.^{6,8,38-40} The implication of a lower risk of severe ICH in SGA birth 243 244 without other anomalies warrants attention given reports of higher risk of neurodevelopmental 245 impairment including poorer cognitive outcomes in this population.⁴¹ Administration of antenatal 246 corticosteroids reduces the risk of severe IVH and mortality, but studies have suggested that steroids in SGA preterm infants may not reduce serious morbidities.^{42,43} Although a previous 247 248 landmark trial reported a potential reduction in severe IVH but no effect on neurosensory 249 impairment with the use of prophylactic indomethacin in extremely low birth weight infants, multiple studies have refuted this finding.⁴⁴⁻⁴⁶ Replication, functional validation, and basic 250 251 investigation into protection of IVH in growth restricted extremely preterm infants may inform 252 novel therapies.

253

Our study had several compelling strengths. This represents the largest and most comprehensive examination of factors associated with preterm SGA status and comorbidities to our knowledge. This was a multicenter investigation of infants from diverse backgrounds, with generalizable results. There are important limitations to this study. Infants born SGA may be more likely to undergo pre- or postnatal genetic testing, especially in the presence of other congenital anomalies or comorbidities. Details regarding testing, including time (pre- or

260 postnatal) and indication are unknown in this cohort. Genetic testing has also undergone 261 dramatic changes from 2000 to 2020. There is likely substantial heterogeneity in the genetic 262 workups performed across this period. Unfortunately, data are not available regarding the 263 spectrum of testing performed in the cohort, including negative results. There may also be 264 heterogeneity in the assignment of gestational age. The method used to determine this for each 265 individual in the cohort is unknown. Additionally, SGA and FGR are defined differently in the 266 literature of this field. We defined SGA birth here using the distribution of birth weight found 267 within this cohort. This definition increases the internal validity or our analysis but may limit 268 generalization. Given that our definition of SGA shared 92.1% with Fenton-defined SGA infants, 269 this is unlikely. The optimal criteria for defining a newborn as SGA or growth restricted likely 270 include individual environmental, genetic, and biological factors, many of which are yet 271 unknown. These analyses also did not consider when growth restriction occurred during 272 pregnancy, patterns of growth restriction (such as head-sparing or symmetric), fetal exposures, 273 postnatal growth patterns, or social determinants of health. Our dataset lacks maternal records, 274 including the presence of comorbidities that may contribute to placental insufficiency. Our 275 finding that extremes of maternal age, as well as increasing maternal age from 18 to 34 years, 276 were associated with SGA status likely reflects the contribution of these maternal factors.

277

Genetic counseling and consideration of testing for FGR is recommended by the American
College of Obstetricians and Gynecologists as well as by the Society for Maternal and Fetal
Medicine.^{47,48} There is not yet consensus regarding the postnatal evaluation of SGA infants.^{49,50}
Scarce data exist regarding how often genetic workups or testing are actually performed pre- or
postnatally for these indications. Furthermore, perinatal genetic disorders often present
nonspecifically and are often diagnosed belatedly.^{51,52} The indications and potential benefit for
genetic testing in this population is unknown without prospective, genome-wide testing.

285

286 Our findings have implications for clinical practice and further research. Clinicians should 287 strongly consider genetic testing of preterm SGA infants, particularly in the setting of other 288 comorbidities or anomalies. Genetic disorders were found in 3.0% of preterm SGA infants 289 overall and 4.3% of preterm SGA infants with severe morbidity and mortality. These represent 290 underestimates as prospective testing was not preformed. Without prospective genetic testing 291 the baseline rate genetic disorders in this population is unknown. Preterm SGA infants with 292 genetic disorders or congenital anomalies may be at higher risk for morbidity and mortality. 293 Clinicians should consider this risk when counseling families, evaluating the risks and benefits 294 of management decisions, or estimating the pre-test probability of diagnostic tests. Prospective 295 genomic research is urgently needed to clarify the contribution of genetic disorders to disease in 296 this population. 297

298

300 Acknowledgements

- 301 The authors wish to gratefully acknowledge Dr. Ali G. Gharavi (Columbia University Irving
- 302 Medical Center) and his research team, as well as Dr. Joseph M. Feinglass (Feinberg School of
- 303 Medicine, Northwestern University) for their mentorship and thoughtful review of this project.

304

- 305 Authors TH and JEM are supported by *Thrasher Research Fund Early Career Awards*. TH is
- 306 also supported by the NIH National Center for Advancing Translational Sciences
- 307 (KL2TR001874).

308

310 Supplemental Materials

- 311 **Supplemental Table 1.** Unadjusted odds of SGA birth within diagnosed genetic disorders.
- 312 **Supplemental Figure 1.** Classification of SGA or FGR birth in this cohort by related criteria.
- 313 **Supplemental Figure 2.** Multivariable logistic regression for SGA versus AGA status in preterm
- 314 infants with singleton gestation.
- 315 **Supplemental Figure 3.** Multivariable logistic regression for severe morbidity or mortality in
- 316 SGA preterm infants following singleton gestation.
- 317 **eMethods.** R studio script used for this project.

318 T a	able 1.	Descriptive	characteristics	of cohort
----------------	---------	-------------	-----------------	-----------

Characteristic	AGA (N=341902)	SGA (N=36985)	P-value
Sex			-
Female	159615 (46.7%)	17176 (46.4%)	0.375
Male	182287 (53.3%)	19809 (53.6%)	
Gestational Age (weeks)			
Mean (SD)	30.1 (2.88)	30.2 (2.69)	<0.001
Median [Min, Max]	31.0 [23.0, 33.0]	31.0 [23.0, 33.0]	
Race and Ethnicity			
Asian	9698 (2.8%)	1152 (3.1%)	<0.001
Black	79022 (23.1%)	10128 (27.4%)	
Hispanic	66839 (19.5%)	6157 (16.6%)	
Other	25385 (7.4%)	2851 (7.7%)	
White	160958 (47.1%)	16697 (45.1%)	
Maternal Age			
Mean (SD)	28.1 (6.52)	28.5 (6.57)	<0.001
Median [Min, Max]	28.0 [10.0, 60.0]	28.0 [10.0, 58.0]	
Missing	1494 (0.4%)	126 (0.3%)	
Discharge Year			
2000 to 2004	56242 (16.4%)	5979 (16.2%)	0.025
2005 to 2009	90974 (26.6%)	9809 (26.5%)	
2010 to 2014	91931 (26.9%)	9810 (26.5%)	
2015 to 2020	102755 (30.1%)	11387 (30.8%)	
Genetic Disorder			
Absent	337628 (98.8%)	35873 (97.0%)	<0.001
Present	4274 (1.3%)	1112 (3.0%)	
Congenital Anomaly			
Absent	321063 (93.9%)	33361 (90.2%)	<0.001
Kidney or urinary tract	5082 (1.5%)	834 (2.3%)	
Heart	5555 (1.6%)	925 (2.5%)	
Central nervous system	3718 (1.1%)	611 (1.7%)	
Gastrointestinal tract	3674 (1.1%)	649 (1.8%)	
Hydrops	321 (0.1%)	36 (0.1%)	
Multiple organ systems	2066 (0.6%)	513 (1.4%)	
Pulmonary	423 (0.1%)	56 (0.2%)	

319 Abbreviations: AGA (appropriate for gestational age), SGA (small for gestational age)

OR (99.44% CI)

Table 2. Unadjusted odds of mortality or severe morbidities in preterm SGA infants.

utcome	Preterm SGA Infants without Congenital	Preterm SGA Infants with Additional Congenital	
	Preterm Infants)	Preterm Infants)	
Mortality or any morbidity	1.45 (1.39, 1.50)	4.86 (4.33, 5.46)	
Mortality	1.99 (1.87, 2.12)	5.96 (5.20, 6.83)	
Acute kidney injury	1.60 (1.46, 1.75)	5.03 (4.22, 6.00)	
Severe intracranial hemorrhage	0.82 (0.75, 0.91)	1.89 (1.52, 2.36)	
Severe necrotizing enterocolitis	1.28 (1.18, 1.40)	3.50 (2.91, 4.21)	
Severe bronchopulmonary dysplasia	2.40 (2.13, 2.70)	9.50 (7.78, 11.59)	
Severe retinopathy of prematurity	1.52 (1.33, 1.74)	3.14 (2.31, 4.27)	
Sepsis	1.37 (1.29, 1.45)	3.22 (2.81, 3.68)	
Shock	1.35 (1.28, 1.43)	3.18 (2.78, 3.64)	

322

321

323

Variable		N	Odds ratio		р
Race and Ethnicity	White	177138	.	Reference	
	Asian	10811		1.10 (1.04, 1.18)	0.002
	Black	88877		1.24 (1.21, 1.28)	< 0.001
	Hispanic	72747		0.89 (0.86, 0.92)	< 0.001
	Other	27694		1.07 (1.03, 1.12)	0.001
Maternal Age (years)	10-19	36857	i	Reference	
	20-29	182044		1.12 (1.08, 1.16)	<0.001
	30-39	142563		1.19 (1.15, 1.24)	< 0.001
	40-49	15600		1.33 (1.25, 1.42)	<0.001
	50-60	203		1.54 (0.98, 2.29)	0.046
Discharge Year	2000 to 2004	62190		Reference	
	2005 to 2009	100052	÷.	1.01 (0.97, 1.04)	0.717
	2010 to 2014	101153		0.98 (0.95, 1.02)	0.329
	2015 to 2020	113872	÷.	1.00 (0.97, 1.04)	0.939
Genetic Disorder	Absent	371906		Reference	
	Present	5361		2.06 (1.92, 2.21)	< 0.001
Congenital Anomaly	Absent	352898	•	Reference	
	Cardiac	6458		1.51 (1.41, 1.62)	< 0.001
	Gastrointestinal	4304	-	1.68 (1.55, 1.83)	<0.001
	Hydrops	356	·	1.03 (0.72, 1.43)	0.869
	Multiple	2568	· = ·	2.18 (1.97, 2.40)	<0.001
	Neurological	4311	-	1.54 (1.41, 1.68)	< 0.001
	Pulmonary	476	, 1	1.28 (0.96, 1.68)	0.081
	Renal	5896		1.58 (1.47, 1.70)	<0.001

325

Figure 1: Multivariable regression of clinical characteristics of preterm infants born SGA versus AGA. Regression was performed for the outcome of SGA birth within infants born before 34 weeks' gestation. Maternal identification as Hispanic was associated with lower adjusted odds of SGA status. Maternal identification as Asian or Black, advancing maternal age, the presence of a known genetic disorder, and the presence of congenital anomalies (excluding hydrops and pulmonary anomalies) were associated with greater adjusted odds of SGA status.

332

Variable		N	Odds ratio		р
Antenatal Betamethasone	No	4688	H	Reference	
	Yes	24295		0.70 (0.64, 0.77)	< 0.001
Sex	Female	13584		Reference	
	Male	15399		1.17 (1.10, 1.25)	< 0.001
Race and Ethnicity	White	13117		Reference	
	Asian	929		0.80 (0.65, 0.98)	0.034
	Black	7955	—	0.88 (0.81, 0.95)	0.001
	Hispanic	4792		1.31 (1.19, 1.44)	< 0.001
	Other	2190		0.93 (0.82, 1.07)	0.320
Gestational Age (weeks)		28983		0.61 (0.60, 0.62)	<0.001
Birth Weight (Z-score)		28983		0.40 (0.37, 0.43)	<0.001
Delivery Mode	Vaginal	2565	H	Reference	
	Cesarean Section	26418		0.64 (0.57, 0.73)	<0.001
Discharge Year	2000 to 2004	4423		Reference	
	2005 to 2009	7773	H	0.98 (0.89, 1.09)	0.734
	2010 to 2014	7883		0.70 (0.63, 0.78)	<0.001
	2015 to 2020	8904		0.62 (0.56, 0.69)	<0.001
Intubation within 72 Hours	No	17689	F	Reference	
	Yes	11294	: •	2.86 (2.66, 3.08)	<0.001
Genetic Disorder	Absent	28193		Reference	
	Present	790		2.12 (1.77, 2.55)	<0.001
Congenital Anomaly	Absent	26645		Reference	
	Cardiac	568		2.07 (1.68, 2.56)	<0.001
	Gastrointestinal	373		5.11 (3.91, 6.71)	<0.001
	Hydrops	24		17.38 (4.93, 85.73)	<0.001
	Multiple	295		8.91 (6.65, 12.01)	<0.001
	Neurological	406		3.36 (2.62, 4.30)	<0.001
	Pulmonary	41	i • •	4.69 (2.23, 10.27)	<0.001
	Renal	631		2.29 (1.87, 2.81)	<0.001
			0.51.2 51020.50		

334 335 Figure 2. Multivariable logistic regression of clinical characteristics of preterm SGA infants with 336 severe morbidity or mortality (versus preterm SGA infants without severe morbidity or mortality). 337 Within the subset of preterm infants born SGA, regression was performed against the combined 338 outcome of mortality or severe morbidity. Antenatal betamethasone, maternal identification as 339 Asian or Black, increasing gestational age, increasing birth weight, cesarean delivery, and later 340 epochs were found to be associated with lower adjusted odds of the composite outcome. Male 341 sex, maternal identification as Hispanic, intubation after birth, and the presence of known 342 genetic disorders or congenital anomalies were associated with greater adjusted odds of the 343 composite outcome.

344



Figure 3. Prevalence of SGA birth by maternal age. The prevalence of SGA birth was determined (within preterm births) for each year of maternal age from 15 to 50. Error bars depict the 95% CI. Extreme maternal ages, less than 15 and greater than 50, were excluded from the analysis due to their small sample size. For each one year increase in maternal age, on average, there was a 0.107 increase in SGA prevalence per 100 preterm births (adjusted $r^2 =$ 0.46, p = <0.001).

- 354
- 355
- 356
- 357

358 References

Bernstein IM, Horbar JD, Badger GJ, Ohlsson A, Golan A. Morbidity and mortality 359 1. 360 among very-low-birth-weight neonates with intrauterine growth restriction. The Vermont Oxford 361 Network. Am J Obstet Gynecol. Jan 2000;182(1 Pt 1):198-206. doi:10.1016/s0002-362 9378(00)70513-8 363 Zeitlin J, El Ayoubi M, Jarreau PH, et al. Impact of fetal growth restriction on mortality 2. 364 and morbidity in a very preterm birth cohort. J Pediatr. Nov 2010;157(5):733-9.e1. 365 doi:10.1016/j.jpeds.2010.05.002 366 Peacock JL, Lo JW, D'Costa W, Calvert S, Marlow N, Greenough A. Respiratory 3. 367 morbidity at follow-up of small-for-gestational-age infants born very prematurely. *Pediatr Res.* 368 Apr 2013;73(4 Pt 1):457-63. doi:10.1038/pr.2012.201 369 De Jesus LC, Pappas A, Shankaran S, et al. Outcomes of small for gestational age 4. 370 infants born at <27 weeks' gestation. J Pediatr. Jul 2013;163(1):55-60.e1-3. 371 doi:10.1016/j.jpeds.2012.12.097 372 5. Garite TJ, Clark R, Thorp JA. Intrauterine growth restriction increases morbidity and 373 mortality among premature neonates. Am J Obstet Gynecol. Aug 2004;191(2):481-7. 374 doi:10.1016/i.aiog.2004.01.036 375 Mendez-Figueroa H, Truong VT, Pedroza C, Chauhan SP. Morbidity and Mortality in 6. 376 Small-for-Gestational-Age Infants: A Secondary Analysis of Nine MFMU Network Studies. Am J 377 Perinatol. Mar 2017;34(4):323-332. doi:10.1055/s-0036-1586502 378 7. Horbar JD, Carpenter JH, Badger GJ, et al. Mortality and neonatal morbidity among 379 infants 501 to 1500 grams from 2000 to 2009. Pediatrics. Jun 2012;129(6):1019-26. 380 doi:10.1542/peds.2011-3028 381 Baer RJ. Rogers EE. Partridge JC. et al. Population-based risks of mortality and preterm 8. 382 morbidity by gestational age and birth weight. J Perinatol. Nov 2016;36(11):1008-1013. 383 doi:10.1038/jp.2016.118 384 Minor KC, Bianco K, Sie L, Druzin ML, Lee HC, Leonard SA. Severity of small-for-9. gestational-age and morbidity and mortality among very preterm neonates. J Perinatol. Apr 385 386 2023;43(4):437-444. doi:10.1038/s41372-022-01544-w 387 Fenton TR. Kim JH. A systematic review and meta-analysis to revise the Fenton growth 10. 388 chart for preterm infants. BMC Pediatr. Apr 20 2013;13:59. doi:10.1186/1471-2431-13-59 389 11. Clayton PE, Cianfarani S, Czernichow P, Johannsson G, Rapaport R, Rogol A. 390 Management of the child born small for gestational age through to adulthood: a consensus 391 statement of the International Societies of Pediatric Endocrinology and the Growth Hormone 392 Research Society. J Clin Endocrinol Metab. Mar 2007;92(3):804-10. doi:10.1210/jc.2006-2017 393 Lee PA, Chernausek SD, Hokken-Koelega AC, Czernichow P. International Small for 12. 394 Gestational Age Advisory Board consensus development conference statement: management 395 of short children born small for gestational age, April 24-October 1, 2001. Pediatrics. Jun 396 2003;111(6 Pt 1):1253-61. doi:10.1542/peds.111.6.1253 397 13. Katz J, Lee AC, Kozuki N, et al. Mortality risk in preterm and small-for-gestational-age 398 infants in low-income and middle-income countries: a pooled country analysis. Lancet. Aug 3 399 2013;382(9890):417-425. doi:10.1016/s0140-6736(13)60993-9 400 14. Finken MJJ, van der Steen M, Smeets CCJ, et al. Children Born Small for Gestational 401 Age: Differential Diagnosis, Molecular Genetic Evaluation, and Implications. Endocr Rev. Dec 1 402 2018;39(6):851-894. doi:10.1210/er.2018-00083 403 McCowan L, Horgan RP. Risk factors for small for gestational age infants. Best Pract 15. 404 *Res Clin Obstet Gynaecol.* Dec 2009;23(6):779-93. doi:10.1016/j.bpobgyn.2009.06.003 405 16. Wollmann HA. Intrauterine growth restriction: definition and etiology. Horm Res. 1998;49 Suppl 2:1-6. doi:10.1159/000053079 406

407 17. Mone F. Mellis R. Gabriel H. et al. Should we offer prenatal exome sequencing for 408 intrauterine growth restriction or short long bones? A systematic review and meta-analysis. Am 409 J Obstet Gynecol. Oct 7 2022;doi:10.1016/j.ajog.2022.09.045 410 Meler E, Sisterna S, Borrell A. Genetic syndromes associated with isolated fetal growth 18. 411 restriction. Prenat Diagn. Mar 2020;40(4):432-446. doi:10.1002/pd.5635 412 Peng R, Yang J, Xie HN, Lin MF, Zheng J. Chromosomal and subchromosomal 19. 413 anomalies associated to small for gestational age fetuses with no additional structural 414 anomalies. Prenat Diagn. Dec 2017;37(12):1219-1224. doi:10.1002/pd.5169 Borrell A, Grande M, Meler E, et al. Genomic Microarray in Fetuses with Early Growth 415 20. 416 Restriction: A Multicenter Study. Fetal Diagn Ther. 2017;42(3):174-180. doi:10.1159/000452217 417 21. Motelow JE, Lippa NC, Hostyk J, et al. Risk Variants in the Exomes of Children With 418 Critical Illness. JAMA Netw Open. Oct 3 2022;5(10):e2239122. 419 doi:10.1001/jamanetworkopen.2022.39122 Stanley KE, Giordano J, Thorsten V, et al. Causal Genetic Variants in Stillbirth. N Engl J 420 22. 421 Med. Sep 17 2020;383(12):1107-1116. doi:10.1056/NEJMoa1908753 422 Petrovski S, Aggarwal V, Giordano JL, et al. Whole-exome sequencing in the evaluation 23. 423 of fetal structural anomalies: a prospective cohort study. Lancet. Feb 23 2019;393(10173):758-424 767. doi:10.1016/S0140-6736(18)32042-7 Lord J, McMullan DJ, Eberhardt RY, et al. Prenatal exome sequencing analysis in fetal 425 24. 426 structural anomalies detected by ultrasonography (PAGE): a cohort study. Lancet. Feb 23 427 2019;393(10173):747-757. doi:10.1016/S0140-6736(18)31940-8 428 Bertoli-Avella AM, Beetz C, Ameziane N, et al. Successful application of genome 25. 429 sequencing in a diagnostic setting: 1007 index cases from a clinically heterogeneous cohort. 430 Eur J Hum Genet. Jan 2021;29(1):141-153. doi:10.1038/s41431-020-00713-9 431 26. Havs T. Wapner RJ. Genetic testing for unexplained perinatal disorders. Curr Opin 432 Pediatr. Apr 1 2021;33(2):195-202. doi:10.1097/MOP.000000000000999 433 27. Spitzer AR, Ellsbury DL, Handler D, Clark RH. The Pediatrix BabySteps Data 434 Warehouse and the Pediatrix QualitySteps improvement project system--tools for "meaningful 435 use" in continuous quality improvement. Clin Perinatol. Mar 2010;37(1):49-70. 436 doi:10.1016/j.clp.2010.01.016 437 Grantz KL, Grewal J, Kim S, et al. Unified standard for fetal growth: the Eunice Kennedy 28. Shriver National Institute of Child Health and Human Development Fetal Growth Studies. Am J 438 439 Obstet Gynecol. Apr 2022;226(4):576-587.e2. doi:10.1016/j.ajog.2021.12.006 440 29. Tolia VN, Clark RH. The Denominator Matters! Lessons from Large Database Research 441 in Neonatology. Children (Basel). Nov 7 2020;7(11):216-216. doi:10.3390/children7110216 442 30. Papile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal 443 and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. J Pediatr. Apr 1978;92(4):529-34. doi:10.1016/s0022-3476(78)80282-0 444 445 Stevenson DK, Verter J, Fanaroff AA, et al. Sex differences in outcomes of very low 31. 446 birthweight infants: the newborn male disadvantage. Arch Dis Child Fetal Neonatal Ed. Nov 447 2000;83(3):F182-5. doi:10.1136/fn.83.3.f182 448 Peacock JL, Marston L, Marlow N, Calvert SA, Greenough A. Neonatal and infant 32. 449 outcome in boys and girls born very prematurely. Pediatr Res. Mar 2012;71(3):305-10. 450 doi:10.1038/pr.2011.50 R: A language and environment for statistical computing. R Foundation for Statistical 451 33. 452 Computing; 2022. https://www.R-project.org/ 453 Schlüter DK, Griffiths R, Adam A, et al. Impact of cystic fibrosis on birthweight: a 34. 454 population based study of children in Denmark and Wales. Thorax. 2019;74(5):447-454.

455 doi:10.1136/thoraxjnl-2018-211706

456 35. Giorgione V, Briffa C, Di Fabrizio C, Bhate R, Khalil A. Perinatal Outcomes of Small for 457 Gestational Age in Twin Pregnancies: Twin vs. Singleton Charts. J Clin Med. Feb 8 458 2021;10(4)doi:10.3390/jcm10040643 459 D'Antonio F, Khalil A, Dias T, Thilaganathan B. Weight discordance and perinatal 36. 460 mortality in twins: analysis of the Southwest Thames Obstetric Research Collaborative (STORK) 461 multiple pregnancy cohort. Ultrasound Obstet Gynecol. Jun 2013;41(6):643-8. 462 doi:10.1002/uog.12412 463 Townsend R, Khalil A. Fetal growth restriction in twins. Best Pract Res Clin Obstet 37. 464 Gynaecol. May 2018;49:79-88. doi:10.1016/j.bpobgyn.2018.02.004 465 Kim F, Bateman DA, Goldshtrom N, Sheen J-J, Garey D. Intracranial ultrasound 38. 466 abnormalities and mortality in preterm infants with and without fetal growth restriction stratified 467 by fetal Doppler study results. Journal of Perinatology. 2023/01/30 2023;doi:10.1038/s41372-468 023-01621-8 Procianov RS, Garcia-Prats JA, Adams JM, Silvers A, Rudolph AJ. Hyaline membrane 469 39. 470 disease and intraventricular haemorrhage in small for gestational age infants. Arch Dis Child. 471 Jul 1980;55(7):502-5. doi:10.1136/adc.55.7.502 472 40. Gilbert WM, Danielsen B. Pregnancy outcomes associated with intrauterine growth 473 restriction. American Journal of Obstetrics and Gynecology. 2003/06/01/ 2003;188(6):1596-474 1601. doi:https://doi.org/10.1067/mob.2003.384 475 41. Sacchi C, Marino C, Nosarti C, Vieno A, Visentin S, Simonelli A. Association of 476 Intrauterine Growth Restriction and Small for Gestational Age Status With Childhood Cognitive 477 Outcomes: A Systematic Review and Meta-analysis. JAMA Pediatr. Aug 1 2020;174(8):772-478 781. doi:10.1001/jamapediatrics.2020.1097 479 Roberts D, Brown J, Medley N, Dalziel SR. Antenatal corticosteroids for accelerating 42. 480 fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev. Mar 21 481 2017;3(3):Cd004454. doi:10.1002/14651858.CD004454.pub3 482 Blankenship SA, Brown KE, Simon LE, Stout MJ, Tuuli MG, Antenatal corticosteroids in 43. 483 preterm small-for-gestational age infants: a systematic review and meta-analysis. Am J Obstet 484 Gynecol MFM. Nov 2020;2(4):100215. doi:10.1016/j.ajogmf.2020.100215 485 44. Schmidt B, Davis P, Moddemann D, et al. Long-term effects of indomethacin prophylaxis 486 in extremely-low-birth-weight infants. N Engl J Med. Jun 28 2001;344(26):1966-72. 487 doi:10.1056/nejm200106283442602 488 45. Mirza H, Laptook AR, Oh W, et al. Effects of indomethacin prophylaxis timing on 489 intraventricular haemorrhage and patent ductus arteriosus in extremely low birth weight infants. 490 Arch Dis Child Fetal Neonatal Ed. Sep 2016;101(5):F418-22. doi:10.1136/archdischild-2015-491 309112 492 46. Foglia EE, Roberts RS, Stoller JZ, Davis PG, Haslam R, Schmidt B. Effect of 493 Prophylactic Indomethacin in Extremely Low Birth Weight Infants Based on the Predicted Risk 494 of Severe Intraventricular Hemorrhage. Neonatology. 2018;113(2):183-186. 495 doi:10.1159/000485172 496 47. Fetal Growth Restriction: ACOG Practice Bulletin, Number 227. Obstet Gynecol. Feb 1 497 2021;137(2):e16-e28. doi:10.1097/aog.000000000004251 498 Martins JG, Biggio JR, Abuhamad A. Society for Maternal-Fetal Medicine Consult Series 48. 499 #52: Diagnosis and management of fetal growth restriction: (Replaces Clinical Guideline 500 Number 3, April 2012). Am J Obstet Gynecol. Oct 2020;223(4):B2-b17. 501 doi:10.1016/j.ajog.2020.05.010 502 Dauber A. Genetic Testing for the Child With Short Stature-Has the Time Come To 49. 503 Change Our Diagnostic Paradigm? J Clin Endocrinol Metab. Jul 1 2019;104(7):2766-2769. 504 doi:10.1210/jc.2019-00019 505 Rapaport R, Wit JM, Savage MO. Growth failure: 'idiopathic' only after a detailed 50. 506 diagnostic evaluation. Endocr Connect. Mar 2021;10(3):R125-r138. doi:10.1530/ec-20-0585

507 51. Clark MM, Stark Z, Farnaes L, et al. Meta-analysis of the diagnostic and clinical utility of 508 genome and exome sequencing and chromosomal microarray in children with suspected

509 genetic diseases. *NPJ Genom Med*. 2018;3(1):16. doi:10.1038/s41525-018-0053-8

510 52. Wojcik MH, Schwartz TS, Yamin I, et al. Genetic disorders and mortality in infancy and

511 early childhood: delayed diagnoses and missed opportunities. Genet Med. Nov

512 2018;20(11):1396-1404. doi:10.1038/gim.2018.17

513

Supplemental Table 1. Unadjusted odd	s of SGA birth as	sociated for sp	ecific genetic disorde
Genetic Disorder	SGA (n)	AGA (n)	OR (99.75% CI)
Aneuploidy			
Trisomy 13	32	109	2.76 (1.50–5.08)
Trisomy 18	145	80	17.06 (11.19-26.00
Trisomy 21	286	987	2.73 (2.22-3.34)
Trisomy 22	1	2	4.71 (0.12-190.89)
Turner syndrome	17	34	4.71 (1.92-11.55)
Klinefelter syndrome	9	35	2.42 (0.78-7.49)
Unspecified aneuploidy	204	554	3.47 (2.70-4.44)
Copy Number Variant			
13q deletion	3	8	3.53 (0.46-27.33)
Cri-du-chat	4	17	2.21 (0.41-11.88)
DiGeorge syndrome	9	54	1.57 (0.53-4.66)
Unspecified copy number variant	15	31	4.55 (1.76-11.79)
Hematologic Single Gene Disorder			
Hemophilia A	1	12	0.78 (0.03-18.25)
Thalassemia	169	1256	1.27 (0.99-1.62)
Hemoglobin Bart's	39	391	0.94 (0.56-1.56)
Sickle cell anemia	48	196	2.30 (1.42-3.75)
G6PD deficiency	32	200	1.51 (0.85-2.68)

Genetic Disorder	SGA (n)	AGA (n)	OR (99.75% CI)
Fanconi anemia	2	1	18.82 (0.46-763.54)
Miscellaneous			
Cystic fibrosis	48	206	2.19 (1.35-3.56)
Hypophosphatasia	41	80	4.82 (2.70-8.62)
Multiple diagnoses	7	9	7.32 (1.60-33.59)

516

517 Abbreviations: AGA (appropriate for gestational age), CI (confidence interval), OR (odds ratio),

518 SGA (small for gestational age)



534

535 **Supplemental Figure 1.** Classification of SGA or FGR birth in this cohort by related criteria.

536 This cohort included 409,399 preterm infants from the Pediatrix CDW. SGA was defined for this

537 study as below the 10th percentile for gestational age and sex within the CDW cohort. 36,985

538 infants met this definition, all of whom were below the 10th percentile for NICHD fetal growth.

539 33,451 (92.1%) of these infants also fell below the Fenton 10th percentile definition of SGA birth.

540 The numbers of infants meeting these criteria are depicted in the Euler diagram above.

542

Variable		N	Odds ratio		р
Race and Ethnicity	White	111314	I	Reference	
	Asian	7672	i i i i i i i i i i i i i i i i i i i	1.02 (0.94, 1.10)	0.7
	Black	67874		1.18 (1.14, 1.22)	< 0.001
	Hispanic	55644		0.82 (0.79, 0.85)	< 0.001
	Other	19812	•	1.03 (0.98, 1.08)	0.3
Maternal Age (years)	10-19	29599		Reference	
	20-29	129969		1.17 (1.12, 1.22)	<0.001
	30-39	92726		1.26 (1.21, 1.32)	<0.001
	40-49	9971		1.39 (1.29, 1.50)	<0.001
	50-60	51		1.16 (0.40, 2.65)	0.8
Discharge Year	2000 to 2004	36019		Reference	
	2005 to 2009	71117		1.02 (0.97, 1.06)	0.5
	2010 to 2014	72055		1.01 (0.97, 1.05)	0.7
	2015 to 2020	83125		1.02 (0.98, 1.07)	0.3
Genetic Disorder	Absent	258130		Reference	
	Present	4186	¦ 🔳	2.09 (1.93, 2.25)	< 0.001
Congenital Anomaly	Absent	243621	H	Reference	
	Cardiac	4665	: 🔳	1.40 (1.28, 1.52)	<0.001
	Gastrointestinal	3506	: 🔳	1.52 (1.38, 1.67)	<0.001
	Hydrops	279	- ₩ -	1.06 (0.71, 1.52)	0.8
	Multiple	2051	: •	1.94 (1.73, 2.17)	<0.001
	Neurological	3455	: 🔳	1.38 (1.25, 1.53)	<0.001
	Pulmonary	360	-t∎	1.29 (0.93, 1.75)	0.1
	Renal	4379		1.56 (1.43, 1.69)	<0.001
			0.5 1 1.5 22.5		

Supplemental Figure 2. Multivariable logistic regression for SGA versus AGA status in preterm

544 infants with singleton gestation. The outcome of preterm SGA status was modeled as before

545 (**Figure 1**) in only infants born following singleton gestation. Nearly identical adjusted odds were

546 found for all covariates.

547

543

548

Variable		N	Odds ratio		р
Antenatal Betamethasone	No	3537		Reference	
	Yes	17542		0.66 (0.60, 0.73)	< 0.001
Sex	Female	9753		Reference	
	Male	11326		1.17 (1.08, 1.26)	< 0.001
Race and Ethnicity	White	8780		Reference	
	Asian	655		0.76 (0.59, 0.96)	0.03
	Black	6290		0.92 (0.84, 1.01)	0.09
	Hispanic	3712		1.44 (1.29, 1.60)	< 0.001
	Other	1642		0.99 (0.85, 1.15)	0.86
Gestational Age (weeks)		21079		0.61 (0.60, 0.62)	< 0.001
Birth Weight (Z-score)		21079		0.38 (0.35, 0.42)	<0.001
Delivery Mode	Vaginal	1948		Reference	
	Cesarean Section	19131		0.60 (0.52, 0.70)	<0.001
Discharge Year	2000 to 2004	2651		Reference	
	2005 to 2009	5683		1.01 (0.89, 1.14)	0.93
	2010 to 2014	5893		0.72 (0.64, 0.82)	< 0.001
	2015 to 2020	6852		0.66 (0.58, 0.75)	<0.001
Intubation within 72 Hours	No	12387	—	Reference	
	Yes	8692		2.85 (2.61, 3.10)	<0.001
Genetic Disorder	Absent	20445		Reference	
	Present	634		2.17 (1.77, 2.66)	<0.001
Congenital Anomaly	Absent	19301		Reference	
	Cardiac	411		2.10 (1.63, 2.69)	<0.001
	Gastrointestinal	292		5.67 (4.17, 7.74)	<0.001
	Hydrops	19		14.69 (3.93, 75.11)	<0.001
	Multiple	222		8.91 (6.37, 12.57)	<0.001
	Neurological	316		3.07 (2.32, 4.06)	<0.001
	Pulmonary	30		7.61 (3.07, 20.95)	<0.001
	Renal	488		1.98 (1.57, 2.50)	<0.001
			0.51.2 51020.50		

Supplemental Figure 3. Multivariable logistic regression for severe morbidity or mortality in

SGA preterm infants following singleton gestation. The combined outcome of mortality or severe

morbidity status for preterm SGA infants was modeled as before (Figure 2) in only infants born

following singleton gestation. Nearly identical adjusted odds were found for all covariates.

```
557
       eMethods
558
559
       The following script was used to generate tables and figures. The script was created using RStudio
560
       (version 2022.07.0).
561
562
       #### Table 1
563
564
       ## Import Data
565
566
        setwd("/Users/Miles/Desktop")
567
        Prevalence <- read.csv("Prev_Update_GxDx.csv")
568
        Prevalence1 <- Prevalence
569
        library(dplyr)
570
        library(table1)
571
572
       ## Data cleaning
573
574
       Prevalence2 <- Prevalence1 %>% filter(BW Z Score <= 1.282)
575
576
       Prevalence3 <- Prevalence2 %>% mutate(SGA = case_when (BW_Z_Score < -1.282 ~ 'SGA',
577
       BW Z Score >= -1.282 ~ 'AGA'))
578
579
       Prevalence4 <- Prevalence3 %>% mutate(Genetic = ifelse(GxDx == "Absent", "Absent", "Present"))
580
581
       Prevalence4$DY <- as.factor(ifelse(Prevalence4$DischargeYear < 2005, "2000 to 2004",
582
       ifelse(Prevalence4$DischargeYear < 2010, "2005 to 2009", ifelse(Prevalence4$DischargeYear < 2015,
       "2010 to 2014", "2015 to 2020"))))
583
584
585
       ## Label Data
586
587
       label(Prevalence4$BW) <- "Birthweight (kg)"
588
       label(Prevalence4$GA) <- "Gestational Age (weeks)"
589
       label(Prevalence4$GxDx) <- "Known Genetic Disorder"
590
       label(Prevalence4$Any Anom) <- "Congenital Anomaly"
591
       label(Prevalence4$SGA) <- "SGA Birth"
592
       label(Prevalence4$Genetic) <- "Genetic Disorder"
593
594
       ## Calculate p-values for Table1
595
596
       pvalue <- function(x, ...) {
597
         # Construct vectors of data y, and groups (strata) g
598
         y \leq -unlist(x)
599
         g \leq factor(rep(1:length(x), times=sapply(x, length)))
600
         if (is.numeric(y)) {
601
          # For numeric variables, perform a standard 2-sample t-test
602
          p \le t.test(y \sim g)p.value
603
         } else {
604
          # For categorical variables, perform a chi-squared test of independence
605
          p \le chisq.test(table(y, g))p.value
606
         }
607
         # Format the p-value, using an HTML entity for the less-than sign.
608
         # The initial empty string places the output on the line below the variable label.
609
         c("", sub("<", "&lt;", format.pval(p, digits=3, eps = 1e-200)))
610
       }
611
612
       ## Table 1
```

```
613
       table1(~ Sex + GA + Race + MaternalAge + DY + Genetic + Any Anom |SGA, data=Prevalence4.
614
615
       overall=F, extra.col=list(`P-value`=pvalue))
616
617
       ####Table 2:
618
619
       ##Inport Data
620
621
       setwd("/Users/Miles/Desktop")
622
       Outcome <- read.csv("Outcome_Update_GxDx.csv")
623
       Outcome1 <- Outcome
624
       library(dplyr)
625
626
       ## Clean the data and make new varriables
627
       Outcome2 <- Outcome1 %>% mutate(SGA = case_when (BW_Z_Score < -1.282 ~ '1', BW_Z Score >= -
628
629
       1.282 ~ '0'))
630
631
       Outcome3 <- Outcome2 %>% filter(BW Z Score <= 1.282)
632
633
       Outcome4 <- Outcome3 %>% mutate(Additional Anom = ifelse(Any Anom == "Absent", "0", "1"))
634
635
       ##Perfom sum calculations
636
       sum(Outcome4$SGA == "1" & Outcome4$Additional Anom == "1" & Outcome4$CritIllorDeath == "Y")
637
       ##Used this model for all the possible scenarios and then put them into an excel sheet
638
       ##Excel Table 2 and Figure 2 were created for export
639
640
       ## Load packages
641
642
       library(tidyverse)
643
       library(pixiedust)
644
       library(kableExtra)
645
       library(webshot)
646
647
       ##Load data
648
649
       Pos <-read.csv("Figure 2 Bonferroni Corrected.csv")
650
651
       tbl1 <- dust(Pos)
652
653
       ##Plot
654
       tbl1 %>%
655
656
        sprinkle colnames(Outcome = "Outcome*", Isolated = "Isolated SGA", Syndromic= "SGA with Additional
657
       Congenital Anomaly") %>%
658
        kable() %>% kable_styling() %>%
659
        add header above(c(" " = 1, "OR (95% CI)" = 2))%>%
660
        kable classic(full width = F, html font = "Arial") %>%
661
        footnote("AKI: acute kidney injury, ICH: intracranial hemorrhage, NEC: necrotizing enterocolitis, BPD:
662
       bronchopulmonary dysplasia, ROP: retinopathy of prematurity", general title = "*Abbreviations")
663
664
       ####Figure 1
665
```

666 ##import data

667 668 setwd("/Users/Miles/Desktop") 669 Prevalence <- read.csv("Prev Update GxDx.csv") 670 Prevalence1 <- Prevalence 671 library(dplyr) 672 673 ##clean data and make new variables 674 675 Prevalence2 <- Prevalence1 %>% filter(BW Z Score <= 1.282) 676 Prevalence3 <- Prevalence2 %>% mutate(SGA = case when (BW Z Score < -1.282 ~ '1', BW Z Score 677 >= -1.282 ~ '0')) 678 Prevalence4 <- Prevalence3 %>% mutate(Genetic = ifelse(GxDx == "Absent", "Absent", "Present")) 679 Prevalence4\$MA <- as.factor(ifelse(Prevalence4\$MaternalAge < 20, "10-19". 680 ifelse(Prevalence4\$MaternalAge < 30, "20-29", ifelse(Prevalence4\$MaternalAge < 40, "30-39", 681 ifelse(Prevalence4\$MaternalAge < 50, "40-49", "50-60"))))) 682 Prevalence4\$Any Anom <- as.factor(ifelse(Prevalence4\$Any Anom == "AG", "Genital", 683 ifelse(Prevalence4\$Any_Anom == "CAKUT", "Renal", ifelse(Prevalence4\$Any_Anom == "CHD", 684 "Cardiac", ifelse(Prevalence4\$Any Anom == "CNS", "Neurological", ifelse(Prevalence4\$Any Anom == 685 "GI", "Gastrointestinal", ifelse(Prevalence4\$Any Anom == "Pulm", "Pulmonary", 686 ifelse(Prevalence4\$Any_Anom == "Hydrops", "Hydrops", ifelse(Prevalence4\$Any_Anom == "Multiple", 687 "Multiple", "Absent"))))))))) 688 Prevalence4\$DY <- as.factor(ifelse(Prevalence4\$DischargeYear < 2005, "2000 to 2004", 689 ifelse(Prevalence4\$DischargeYear < 2010, "2005 to 2009", ifelse(Prevalence4\$DischargeYear < 2015, "2010 to 2014", "2015 to 2020")))) 690 691 692 ##load packages 693 694 library(Hmisc) 695 library(expss) 696 library(qtsummary) 697 library(forestmodel) 698 library(Ime4) 699 700 ##label data 701 702 Prevalence4\$DischargeYear <- factor(Prevalence4\$DischargeYear) 703 Prevalence4\$Race <- factor(Prevalence4\$Race) 704 705 Prevalence4\$Race <- relevel(Prevalence4\$Race, ref = "White") 706 Prevalence4\$SGA <-factor(Prevalence4\$SGA) 707 Prevalence4\$Race <- factor(Prevalence4\$Race)</pre> 708 Prevalence4\$Sex <- factor(Prevalence4\$Sex) 709 Prevalence4\$Any_Anom <- factor(Prevalence4\$Any_Anom) 710 Prevalence4\$MA <- factor(Prevalence4\$MA) 711 Prevalence4\$DY <- factor(Prevalence4\$DY) 712 713 label(Prevalence4\$MA) <- "Maternal Age (years)" 714 label(Prevalence4\$Race) <- "Race and Ethnicity" 715 label(Prevalence4\$Genetic) <- "Genetic Disorder" 716 label(Prevalence4\$Any Anom) <- "Congenital Anomaly" 717 label(Prevalence4\$DY) <- "Discharge Year" 718 719 ##multiple variable logistic regression model 720 LogReg3 <- glm(SGA~ Race + MA + DY + Genetic + Any Anom, data = Prevalence4, family = 721 "binomial")

722 ##table depiction of model

723 forest model(LogReg3, factor separate line = FALSE) 724 725 ####Figure 2: 726 727 ##Load data 728 729 setwd("/Users/Miles/Desktop") 730 Outcome <- read.csv("Outcome Update GxDx.csv") 731 Outcome1 <- Outcome 732 library(dplyr) 733 734 ##data preparation 735 736 Outcome2 <- Outcome1 %>% filter(BW Z Score <= 1.282) 737 Outcome3 <- Outcome2 %>% mutate(SGA = case when (BW Z Score < -1.282 ~ '1', BW Z Score >= -738 1.282 ~ '0')) 739 Outcome4 <- Outcome3 %>% mutate(Genetic = ifelse(GxDx == "Absent", "Absent", "Present")) 740 Outcome5 <- Outcome4 %>% filter(SGA == "1") 741 Outcome5\$DY <- as.factor(ifelse(Outcome5\$DischargeYear < 2005, "2000 to 2004", 742 ifelse(Outcome5\$DischargeYear < 2010, "2005 to 2009", ifelse(Outcome5\$DischargeYear < 2015, "2010 743 to 2014", "2015 to 2020")))) 744 Outcome6 <- Outcome5 %>% mutate(AntSter = ifelse(Antenatal.Steroids == "0", "No", "Yes")) 745 Outcome7 <- Outcome6 %>% mutate(MV72 = ifelse(MVD0.2 == "N", "No", "Yes")) 746 Outcome8 <- Outcome7 %>% filter(Deliv Mode == "Cesarean Section" | Deliv Mode == "Vaginal 747 Delivery") 748 749 ##load required packages 750 751 library(expss) 752 library(gtsummary) 753 library(forestmodel) 754 library(lme4) library(Hmisc) 755 756 757 ##Label data 758 Outcome8\$Sex <- factor(Outcome8\$Sex) 759 760 Outcome8\$Race <- factor(Outcome8\$Race) 761 Outcome8\$AntSter <- factor(Outcome8\$AntSter) 762 Outcome8\$CritIllorDeath <- factor(Outcome8\$CritIllorDeath) 763 Outcome8\$MV72 <- factor(Outcome8\$MV72) 764 Outcome8\$DY <- factor(Outcome8\$DY) 765 766 Outcome8\$Sex <- relevel(Outcome8\$Sex, ref = "Female") 767 Outcome8\$Race <- relevel(Outcome8\$Race, ref = "White") 768 769 label(Outcome8\$AntSter) <- "Antenatal Steroids" 770 label(Outcome8\$Race) <- "Race and Ethnicity" 771 label(Outcome8\$Genetic) <- "Genetic Disorder" 772 label(Outcome8\$Any Anom) <- "Congenital Anomaly" 773 label(Outcome8\$DY) <- "Discharge Year" 774 label(Outcome8\$MV72) <- "MV within 72 Hours" 775 label(Outcome8\$GA) <- "Gestational Age (weeks)" 776 label(Outcome8\$BW Z Score) <- "Birth Weight (Z-score)" 777

778 ## multiple variable logistic regression model 779 780 LogReg <- glm(CritIllorDeath ~ AntSter + Sex + Race + GA + BW Z Score + Deliv Mode + DY + MV72 781 + Genetic + Any Anom, data = Outcome8, family = "binomial") 782 783 ##table depiction of model 784 785 forest model(LogReg, factor separate line = FALSE) 786 787 ####Figure 3: 788 789 ##load data 790 791 setwd("/Users/Miles/Desktop") 792 Prevalence <- read.csv("MA V Prev per 100 Garphing.csv") 793 Prevalence1 <- Prevalence 794 795 ##uplaod required packages 796 797 library(dplyr) 798 library("ggplot2") 799 800 801 ##define and make plot 802 803 df <- ggplot(Prevalence1, aes(MA, Prev Per 100)) + geom point() + geom errorbar(aes(ymin = 804 Low per 100, ymax = Upp per 100)) 805 806 df + geom point() + scale x continuous(breaks=seg(0, 60, 5)) + labs (x = 'Maternal Age (Years)', y = 807 'SGA Prevalence per 100 Preterm Births') + theme bw() + theme(panel.border = element blank(), 808 panel.grid.major = element blank(), 809 panel.grid.minor = 810 element blank(), axis.line = element line(colour = "black")) 811 812 ####Running a linear regression 813 Reg <- Im(Prev per 100 ~ MA, data = MA V Prev per 100 Graphing.csv) 814 ##Review the results 815 Summary(Reg) 816 817 818 ####Supplemental table 1 819 ##Inport Data 820 821 setwd("/Users/Miles/Desktop") 822 GxDx <- read.csv("Updated GxDx SGA.csv") 823 824 ##Upload Packages

```
825
826
       librarv(dplvr)
827
       library(tidyverse)
828
       library(pixiedust)
829
       librarv(kableExtra)
830
       library(webshot)
831
832
       ##Make Table Backend
833
834
       GxDx2 <- replace(GxDx, is.na(GxDx), "")
835
836
       tbl3 <- dust(GxDx2)
837
838
839
       ##Make the Table
840
841
       tbl3 %>%
842
          sprinkle colnames(Genetic.Diagnosis = "Genetic Diagnosis", SGA = "SGA", AGA= "AGA", Crude.OR
843
       = "Crude OR", X95 low = "Low 95 CI", X95 high = "High 95 CI") %>% kable() %>% kable styling()
844
       %>%
845
          kable classic(full width = F, html font = "Arial") %>%
846
          row spec(1,bold=T,hline after = T) %>%
847
          row spec(9,bold=T,hline after = T) %>%
848
          row spec(14,bold=T,hline after = T) \%>%
849
          row spec(21.bold=T.hline after = T) \%>%
850
       add indent(c(2,3,4,5,6,7,8,10,11,12,13,15,16,17,18,19,20,22,23,24))
851
852
       ####Supplemental Figure 1
853
854
       ## Load package
855
       library(eulerr)
856
857
       ## enter numbers of individuals in interaction of sets
858
       fit1 <- euler(c("CDW"=0, "Fenton" = 0, "NICHD"=68986,
859
                 "CDW&Fenton"=0, "Fenton&NICHD"=3534, "CDW&NICHD"=2866,
860
                 "CDW&Fenton&NICHD"=33451))
861
       ## plot Euler diagram
862
       plot(fit1, quantities = TRUE, legend = TRUE)
863
864
       ####Supplemental Figure 2
865
       ##Same code as Figure 1 but added one line of code in data preparation
866
867
       Prevalence4 <- Prevalence4 %>% filter(BirthNumber == "1")
868
869
       ####Supplemental Figure 3
870
       ##Same code as Figure 2 but added one line of code in data preparation
871
       Outcome8 <- Outcome8 %>% filter(BirthNumber == "1")
872
873
       ####Figure 1 Interaction Test
874
       LogReg3 <- glm(SGA~ Race + MA + DY + Genetic + Any Anom + Genetic*Any Anom, data =
875
       Prevalence4, family = "binomial")
876
       anova(LogReg3, test='Chisq')
877
       summary(LogReg3)
878
879
       ####Figure 2 Interaction Test
```

- 880 LogReg5 <- glm(CritIllorDeath ~ Antenatal.Steroids + Sex + Race + GA + MVD0.2 + Any_Anom + DY +
- 881 BW_Z_Score + Genetic + Deliv_Mode + Any_Anom + Genetic*Any_Anom, data = Outcome8,
- 882 family = "binomial")
- 883 anova(LogReg5, test='Chisq')
- 884 summary(LogReg5)
- 885
- 886
- 887